Clinical Trials Logo

Cholangitis, Sclerosing clinical trials

View clinical trials related to Cholangitis, Sclerosing.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04015310 Withdrawn - Clinical trials for Primary Sclerosing Cholangitis

Quantitative Magnetic Resonance Imaging in Biliary Disease: Health Economics Study

BISECT
Start date: December 21, 2020
Phase:
Study type: Observational

This is a health economic study on using quantitative magnetic resonance imaging in biliary disease. It is an observational study aiming to recruit 40 patients with Primary Sclerosing Cholangitis (PSC) in 12 months. The aim of the study is to assess the effect of result of enhanced Magnetic Resonance Cholangiopancreatography (MRCP+) on the physicians' diagnosis and/or plans for patients with suspected or confirmed PSC, compared with usual standard of care. This study also aims to identify the cost-effectiveness of adding MRCP+ to the standard care pathway.

NCT ID: NCT03678480 Withdrawn - Clinical trials for Primary Sclerosing Cholangitis

A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, active-controlled, parallel-group study of HTD1801 in adolescents.

NCT ID: NCT03216876 Withdrawn - Clinical trials for Primary Sclerosing Cholangitis

A Study Of Ursolic Acid For Primary Sclerosing Cholangitis

Start date: September 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, active treatment trial to determine the pharmacokinetics of orally administered ursolic acid and to assess the potential efficacy and safety of ursolic acid in subjects with primary sclerosing cholangitis (PSC).

NCT ID: NCT03046901 Withdrawn - Clinical trials for Primary Sclerosing Cholangitis

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

Start date: December 7, 2016
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate the safety and efficacy of oral vancomycin in patients with recurrent Primary Sclerosing Cholangitis (PSC) after liver transplantation. The primary endpoint is looking at the effect of the drug on liver function tests, an important surrogate of PSC disease activity at 12 weeks on treatment. Secondary endpoints include a decrease in liver function tests at 1 year, changes in bilirubin and adverse events. Effective treatment at the onset of PSC recurrence may lead to decreases in disease progression, recurrent liver failure, and repeat liver transplantation.

NCT ID: NCT03035058 Withdrawn - Clinical trials for Inflammatory Bowel Disease

Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease

Start date: February 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) in non-end-stage primary sclerosing cholangitis (PSC) participants with underlying inflammatory bowel disease (IBD).

NCT ID: NCT00588458 Withdrawn - Clinical trials for Primary Sclerosing Cholangitis

The Value of CT Cholangiography in Primary Sclerosing Cholangitis

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The reason for this study is to see if a new radiologic technique called computerized tomographic cholangiography (CT cholangiography) could be helpful to demonstrate the bile ducts features and measure the amount of space of bile duct canals that should be filled with bile fluid. It may be useful to find out how well these findings correlate with the previously known clinical predictors in term of the clinical outcomes that will happen in the future for patients with primary sclerosing cholangitis (PSC).